Helen Robinson

Title: Helen Robinson: Innovator in Cancer Treatment

Introduction

Helen Robinson is a notable inventor based in Cambridge, GB. She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic methods. Her work focuses on exploiting synthetic lethality and enhancing the effectiveness of chemotherapy.

Latest Patents

Helen Robinson holds a patent for "Methods of screening and treatment with USP4 inhibitors." This patent relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitization in DNA damage response (DDR) pathways. Specifically, it addresses the ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. The patent describes the use of USP4 inhibitors in cancer treatment, particularly for tumors that are defective in double-strand break repair (DSBR) and/or resistant to platinum-based chemotherapy. Additionally, it discusses methods to sensitize tumors to other therapeutic agents.

Career Highlights

Throughout her career, Helen has worked with prominent companies such as Mission Therapeutics Limited and Cambridge Enterprise Limited. Her experience in these organizations has allowed her to advance her research and contribute to the development of innovative cancer therapies.

Collaborations

Helen has collaborated with notable colleagues, including Xavier Jacq and Yaara Ofir-Rosenfeld. These partnerships have enriched her research and expanded the impact of her work in the field of cancer treatment.

Conclusion

Helen Robinson is a pioneering inventor whose work in cancer treatment through USP4 inhibitors showcases her commitment to advancing medical science. Her contributions are vital in the ongoing fight against cancer, and her innovative approaches continue to inspire future research.